I think the complexity of the issue isn't really reflected by the article. The most obvious points that are missing are the risks associated with developing a new drug, the costs of research, and the regulatory requirements from the FDA

Since pharmaceutical companies are, for the most part, publicly traded they're beholden to stock holders to create a profit. If they stop doing that they're in trouble

If the ability to generate profit from developing new drugs are limited, they'll simply stop doing it

Personally I think this kind of profit incentive for healthcare is perverse and ultimately doesn't serve public interest, but until the systemic issues behind these prices are addressed, I find it difficult to see a solution that'll ultimately benefit the end-user